Biological and clinical effects of anti-TNFα treatment

Autoimmunity Reviews

Volumn 7, Issue 1, 2007, Pages 35-41

  Valesini, G ^a   Iannuccelli, C ^a   Marocchi, E ^a   Pascoli, L ^a   Scalzi, V ^a   Di Franco, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti TNF ; Autoantibodies; Neutralizing antibodies; Rheumatoid arthritis; Spondyloarthritis

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BIOLOGICAL FACTOR; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; INFLIXIMAB; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; CHRONIC INFLAMMATION; CLINICAL EFFECTIVENESS; CROHN DISEASE; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; HUMAN; PATHOGENESIS; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; ULCERATIVE COLITIS; UVEITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CHRONIC DISEASE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35448935612     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2007.03.003     Document Type: Review

References (40)

1. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 21 2 (2003) 241-248
2. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.Y., Shealy D., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301 2 (2002) 418-426
3. Moreland L.W., Schiff M.H., Baumgartner S.W., Tindall E.A., Fleischmann R.M., Bulpitt K.J., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130 6 (1999) 478-486
4. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. TEMPO study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 9410 (2005) 675-681
5. Genovese M.C., Bathon J.M., Fleischmann R.M., Moreland L.W., Martin R.W., Whitmore J.B., et al. Long-term safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 32 7 (2005) 1232-1242
6. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 22 (2000) 1594-1602
7. St Clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 11 (2004) 3432-3443
8. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., van Zeben D., Kerstens P.J., Hazes J.M., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52 11 (2005) 3381-3390
9. van de Putte L.B., Atkins C., Malaise M., Sany J., Russell A.S., van Riel P.L., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63 5 (2004) 508-516
10. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 1 (2003) 35-45
11. Furst D.E., Schiff M.H., Fleischmann R.M., Strand V., Birbara C.A., Compagnone D., et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30 12 (2003) 2563-2571
12. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 5 (May 2004) 1400-1411
13. Burmester G.R., Monteagudo Saez I., Malaise M.G., Canas da Silva J., Webber D.G., and Kupper H. Adalimumab (Humira®) is effective in patients who have previously been treated with TNF-antagonists (etanercept and/or infliximab) in widespread clinical practice: 12-week outcomes in the ReAct trial. Ann Rheum Dis 64 Suppl III (2005) 423
14. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 1 (2002) 26-37
15. Maksymowych W.P., Jhangri G.S., Lambert R.G., Mallon C., Buenviaje H., Pedrycz E., et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 29 5 (2002) 959-965
16. van der Heijde D., Dijkmans B., Geusens P., Sieper J., DeWoody K., Williamson P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52 2 (2005) 582-591
17. Gorman J.D., Sack K.E., and Davis Jr. J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346 18 (2002) 1349-1356
18. Heiberg M.S., Nordvag B.Y., Mikkelsen K., Rodevand E., Kaufmann C., Mowinckel P., et al. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 52 8 (2005) 2506-2512
19. Genovese M.C., Mease P.J., Thomson G.T.D., Kivitz A.J., Perdok R.J., and Weinberg M.A. Adalimumab efficacy in patients with psoriatic arthritis who failed prior DMARD therapy. Ann Rheum Dis 64 Suppl III (2005) 313
20. Kavanaugh A., Tutuncu Z., and Catalan-Sanchez T. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. Curr Opin Rheumatol 18 4 (Jul 2006) 347-353
21. Hale S., and Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 33 4 (2006) 231-237
22. Guignard S., Gossec L., Salliot C., Ruyssen-Witrand A., Luc M., Duclos M., and Dougados M. Efficacy of tumor necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 65 12 (2006) 1631-1634
23. De Rycke L., Baeten D., Kruithof E., Van den Bosch F., Veys E.M., and De Keyser F. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 14 (2005) 931-937
24. Smeets T.J., Kraan M.C., van Loon M.E., and Tak P.P. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 48 (2003) 2155-2162
25. Goedkoop A.Y., Kraan M.C., Teunissen M.B., et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 63 (2004) 769-773
26. Catrina A.I., Trollmo C., Klint E., et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52 (2005) 61-72
27. Gershow D., Kim S., Brot N., and Elkon K.B. C-reactive protein binds to apoptotic cells, protect the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192 (2000) 1353-1364
28. Cohen P.L., Caricchio R., Abraham V., et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 196 (2002) 135-140
29. Caramaschi P., Biasi D., Colombatti M., et al. Anti-TNFα therapy in rheumatoid arthritis and autoimmunity. Rheumatol Int 26 (2006) 209-214
30. Shakoor N., Michalska M., Harris C.A., and Block J.A. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359 9306 (2002) 579-580
31. De Rycke L., Van Damme N., Kruitof E., et al. antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondyloarthritis. Arthritis Rheum 48 (2003) 1015-1023
32. Atzeni F., Sarzi-Puttini P., Dell' Acqua D., de Portu S., Cecchini G., Cruini C., Carrabba M., and Meroni P.L. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 8 1 (2006) R3
33. Eriksson C., Engstrand S., Sundqvist K.G., and Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 64 (2005) 403-407
34. Wolbink G.J., Vis M., Lems W., et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54 (2006) 711-715
35. Alessandri C., Bombardieri M., Papa M., et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63 10 (2004) 1218-1221
36. Chen H.A., Lin K.C., Chen C.H., Liao H.T., Wang H.P., Chang H.N., Tsai C.Y., and Chou C.T. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 65 1 (2006) 35-39
37. Braun-Moscovici Y., Markovits D., Zinder O., et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 33 3 (2006) 497-500
38. Valesini G. Are there differences among anti-TNFalpha biological drugs?. Reumatismo 57 Suppl 1(4) (2005) 1-2
39. Valesini G., Montecucco C., and Cutolo M. Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy. Clin Exp Rheumatol 24 4 (2006) 413-423
40. Scott D.L., and Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355 7 (2006) 704-712